Media & News
Septa-Citalopram and Septa-Amlodipine now available in provinces of Ontario, Quebec, and British Columbia
FOR IMMEDIATE RELEASE MISSISSAUGA, ONTARIO - SEPTEMBER 12, 2019 - Septa Pharmaceuticals, Inc. today announced the listing of two of its generic pharmaceutical drugs in the provincial formularies of Ontario, Quebec, and British Columbia. Septa-Citalopram, an Anti-depressant belonging to the pharmaceutical class of Selective Serotonin Reuptake Inhibitors (SSRIs) and used in the treatment of symptoms related to major depression is available in two strengths - 20mg and 40mg in pack sizes of 100 and 500 tablets, respectively in all of the three provinces. Septa-Amlodipine, an Anti-hypertensive/Anti-anginal belonging to the pharmaceutical class of Calcium Channel Blocker is available in three strengths - 2.5mg, 5.0mg, and 10.0mg with pack sizes varying from 100, 250, and 500 tablets. All three strengths are available in provinces. "This major achievement marks a pivotal step for Septa Pharmaceuticals, Inc. as an up and coming generic pharmaceutical company in the Canadian healthcare industry,†said Devinder Kumar, President and CEO of Septa Pharmaceuticals. “Being able to achieve this objective in just less than two years’ time shows the strength, dedication, and commitment of Septa’s team as well as the strong relations and partnerships we have been able to establish with our suppliers and manufacturers, both domestically and globally." For additional information on the listing of Septa Pharmaceuticals’ products, please visit the following provincial formularies. Visitors, members of the public, and health industry professionals are encouraged to visit the products page of Septa Pharmaceuticals to view current and upcoming products being offered by the company. ABOUT SEPTA PHARMACEUTICALS, INC. Septa Pharmaceuticals, Inc. is proudly a Canadian owned and operated generic pharmaceutical company. The company provides quality generic pharmaceuticals and healthcare products for domestic and global pharmaceutical and health care markets. For more information, visit www.septapharmaceuticals.com MEDIA CONTACT Septa Pharmaceuticals, Inc. Public Relations Manager +1.905.564.5665 pr@septapharma.com |